We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 96

Universities abroad experiment with no-fee licensing to drive biotech partnerships

  • Shook Hardy & Bacon LLP
  • -
  • Australia, Canada, European Union, United Kingdom, USA
  • -
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

The proposed Europe-Thailand Free Trade Agreement: IP and pharmaceuticals

  • Tilleke & Gibbins
  • -
  • Thailand, United Kingdom
  • -
  • February 19 2013

In the next few months, the European Union (EU) is seeking to open free trade agreement (FTA) talks with Thailand. Thailand exports more goods to

Intellectual property & life sciences 2013: legal developments you need to know about

  • Mayer Brown LLP
  • -
  • European Union, United Kingdom
  • -
  • January 10 2013

Since 1 January 2013 data processors have been able to implement BCRs to facilitate the movement of personal data outside the EU. The Article 29

BLG Monthly Update

  • Borden Ladner Gervais LLP
  • -
  • Argentina, Australia, Canada, United Kingdom, USA
  • -
  • December 19 2012

The BLG Monthly Update is a digest of recent developments in the law which Neil Guthrie, our National Director of Research, thinks you will find

British man imprisoned in ‘Operation Singapore’ investigation

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • May 3 2011

The UK MHRA's 'Operation Singapore' investigation into the infiltration of counterfeit medicine into the UK's supply chain during five months in 2007 has concluded with a British man being sentenced to eight years imprisonment

Pharmaceutical package anti-counterfeiting directive

  • Fasken Martineau DuMoulin LLP
  • -
  • European Union, United Kingdom
  • -
  • July 26 2010

Counterfeiting of medicinal products is an increasing problem, particularly in the developing world

Divergences in industrial applicability between the United Kingdom and the European Patent Office

  • McDermott Will & Emery
  • -
  • European Union, United Kingdom
  • -
  • April 30 2010

Rejecting an appeal by Human Genome Sciences Inc (HGS), the Court of Appeal of England and Wales in Eli Lilly and Co v Human Genome Sciences Inc 2010 EWCA Civ 33 upheld the finding that HGS' patent (as amended) was invalid for lack of industrial applicability

Cosmetic treatment not excluded as treatment by surgery

  • McDermott Will & Emery
  • -
  • United Kingdom
  • -
  • April 30 2010

In Virulite Distribution Ltd (IPO) BL O05810 12 February 2010, Virulite Distribution Ltd sought to patent a method of treating skin cosmetically to remove wrinkles using light at a very specific wavelength

“Pozzoli windsurfing” tests and problem-and-solution approaches to obviousness

  • McDermott Will & Emery
  • -
  • United Kingdom
  • -
  • April 30 2010

In Actavis UK Ltd v Novartis AG 2010 EWCA Civ 82, the Court of Appeal of England and Wales upheld the decision of Mr Justice Warren that Novartis' European Patent for a sustained release version of a drug was invalid for obviousness over an immediate release formulation

Parallel proceedings: application to stay and identity of parties

  • McDermott Will & Emery
  • -
  • United Kingdom
  • -
  • March 31 2010

In Mölnlycke Health Care AB v BSN Medical Ltd 2009 EWHC 3370, Mr Justice Floyd rejected an application by BSN Medical Ltd to stay proceedings brought by Mölnlycke Health Care AB (MAB) and its exclusive United Kingdom licensee, Mölnlycke Health Care Ltd (MUK), to await a determination of co-pending proceedings in the Stockholm District Court

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy